INTRODUCTION
Primary hyper-immunoglobulin M (IgM; HIGM) syndrome is a heterogeneous group of rare immunodeficiencies defined by normal-to-elevated serum IgM levels with corresponding lowto-absent levels of circulating IgG, IgA, and IgE antibodies. The defect in the production of most isotypes renders affected individuals susceptible to recurrent and severe bacterial and viral infections (reviewed in refs. [1, 2] ). The most prevalent form of HIGM syndrome is X-linked and associated with an impaired CD40 ligand (CD40L) gene function [3] [4] [5] [6] [7] [8] . The lack of "switched" antibodies in HIGM1 patients is a consequence of the absence of CD40L:CD40 contact, which is required for antigen-selected B cells to undergo class-switch recombination (CSR; reviewed in refs. [9, 10] ). Less-common forms of HIGM occur sporadically or as an effect of autosomal recessive transmission (reviewed in ref. [11] ). Examples include HIGM2, which results from mutations in the "activation-induced cytidine deaminase" (AID) protein required for CSR and somatic mutation [12] [13] [14] ; HIGM3, which is caused by mutations in CD40 [15] ; uracil-N glycosylase-dependent HIGM; and a second X-linked form associated with anhidrotic ectodermal dysplasia, associated with mutations in the nuclear factor-B essential modulator or inhibitor of B kinase-␥ gene [16 -18] . The engagement of the CD40 signal transduction pathway or CD40-mediated functions, such as CSR, in different forms of HIGM underscores the critical role CD40 plays in bringing about the development of humoral and cell-mediated immunity.
We have previously characterized lymphocyte expression and function in a female patient (pt1) with a diagnosis of non-X-linked HIGM syndrome [19] . Our analysis revealed a major defect associated with B cell activation, which involved a subset of CD40-induced responses. Specifically, we observed selective impairment of CD40-mediated CD23 expression, germ-line I␥ transcription, and CSR but normal CD80 expression in primary B cells activated with CD4 ϩ T cells. These observations, along with results showing normal CD40 and AID in pt1 B cells (data not shown) and complementation of the defect in vitro by extended signaling through CD40 [19] , strongly suggested that the pt1 defect was related directly to an inability of B cells to integrate a normal threshold of CD40 activation signals.
To extend our understanding of the pt1 B cell phenotype, we sought to use a long-term culture system that recapitulated the CD40 signaling defect. To this end, experiments were initiated to establish Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs), which retained many of the properties of activated B cells including the expression of B cell activation molecules CD23, CD30, and CD44, cellular adhesion molecules, intercellular adhesion molecule-1 (ICAM-1), lymphocyte function-associated antigen-1 (LFA-1), and LFA-3, and an array of cytokines involved in B cell differentiation from lymphoblastoid to plasmacytoid cells [20 -28] . In vitro infection of resting B cells by EBV efficiently drives cells out of quiescence and into a continuously dividing CD23 hi /CD38 lo population, which undergoes limited differentiation upon autonomous growth in culture [21, 29] . One of the six viral proteins essential for immortalization is latent membrane protein-1 (LMP1), which acts as a constitutively active receptor by signaling through the tumor necrosis factor receptor (TNFR)-associated factors (TRAFs) [30 -35] . These adaptor proteins are required for transmitting signals from CD40 (and other TNFR family members) for selective proliferation, activation, and apoptosis (reviewed in ref. [36] ). It is important that expression of LMP1 in B cells induces many of the same cellular functions as CD40 and therefore, to a large extent, engages common signaling pathways to target a specific set of activation-induced genes.
In our current study, we have used two different sets of LCLs to extend our understanding of the pt1 defect relative to CD23 expression and proliferation. CD23 is the low-affinity IgE receptor, which is expressed rapidly on B cells in response to interleukin-4 and T cell contact (reviewed in ref. [37] ). In EBV infection, CD23 mRNA and protein expression are rapidly induced and remain at a high level in the vast majority of LCLs [22, 23] . CD23 has been implicated in playing a central role in EBV immortalization based on the observations that transformed cells only arise from infected cells that express CD23, and a nontransforming mutant virus fails to induce CD23 in infected cells [23, 38] . In addition, resting B cells are induced to proliferate in response to LMP1 signaling and CD40 ligation during T-dependent responses (reviewed in ref. [39] ).
We demonstrate that the activation defect relating to decreased CD23 expression in pt1 B cells is reversed in standard pt1 LCLs after an extended time in culture. In contrast, establishment of pt1 EBV-transformed B cell lines with regulated LMP1 expression resulted in a cell population that retains low CD23 expression and fails to respond to proliferative signals through CD40. These findings validate the LCL tet cells as a model system to study normal and affected CD40-mediated signaling pathways within the context of EBV immortalization of human B cells.
MATERIALS AND METHODS

Cell lines and culturing conditions
Cells (293) are derived from human embryonic kidney cells [American Type Culture Collection (ATCC), Manassas, VA]. The CD40L expressing a 293 cell line (293/CD40L) was constructed by the stable transfection of pCT-BAM into 293 cells as described previously [40] . HH514 is a single-cell clone of the Burkitt's lymphoma cell line P3HR1 [41] . WI38, a human fibroblast cell line, was purchased from ATCC. B cell lines were grown in RPMI-1640 culture medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-glutamine, and 1% penicillin/streptomycin (RPMI-Complete). Lines 293, 293/CD40L, and WI38 were grown in Dulbecco's modified Eagle's mediumComplete media in the same conditions as described above.
Generation of LCLs
Normal donor and pt1 samples of peripheral blood were separated by FicollHypaque gradient centrifugation to recover peripheral blood mononuclear cells (PBMCs; 1ϫ10 7 ), which were added to 5 ml supernatant harvested from the EBV-transformed marmoset cell line B95-8 [42] . Following a 1-h incubation at 37°C, 5 ml RPMI-Complete and 5 g cyclosporine A were added. The cultures were incubated for 14 -21 days until aggregates were visible. Control LCLs (C3121, C3688, and C1125) were randomly selected from cultures that were transformed on approximately the same date as pt1 B cells. Control-and pt1-LCLs were continually expanded in RPMI-Complete for 1 month prior to analysis. For surface expression studies, cells were analyzed at 5 weeks post-transformation. For time-course studies, cells were grown for an additional 4 weeks in culture.
Mini-EBV transformation (LCL tet ) of primary B cells with recombinant plasmid p1852 was performed as described previously [43] with modifications. The p1852 mini-EBV plasmid consists of the coding sequence of the wild-type LMP1 gene under the control of an artificial promoter whose activity can be regulated by a chimeric transcriptional repressor, tetracycline repressor-Kruppel-associated box (tetR-KRAB), in a tetracycline-dependent manner. In addition, 10 other viral genes [EBV nuclear antigen 1 (EBNA1), EBNA-leader protein, EBNA2, EBNA3A, -B, -C, LMP2A, -B, EBV-encoded, small RNAs (EBER)1, and EBER2), generally expressed in the latent phase of the EBV life-cycle, are included in the plasmid and expressed under their own promoters and therefore not regulated by tetR-KRAB.
Briefly, HH514 cells (1ϫ10 7 ) were cotransfected with 20 g p1852 plasmid and 10 g plasmid cytomegalovirus (pCMV)-BZLF1. Electroporation was performed at 960 F and 250 V. Virus released into the supernatant was collected 5 days later. PBMCs isolated from peripheral blood samples by centrifugation on a Ficoll-Paque gradient were infected with virus from HH514 and plated at a dilution of 5 ϫ 10 6 cells/well in a 96-well plate in RPMIComplete medium supplemented with 1 g/ml tetracycline and 1 mM sodium pyruvate on a lethally irradiated (50 Gy) WI38 feeder cell layer. For the first 4 weeks of culture, medium was also supplemented with cyclosporin A (0.5 g/ml). The absence of P3HR1 helper virus in immortalized B cell clones was verified by polymerase chain reaction (PCR) analysis [44] .
Surface expression analysis
LCLs or LCL tet cells (5ϫ10 5 ), cultured in the presence or absence of soluble human CD40L (500 ng/ml, Peprotech Inc., Rocky Hill, NJ), were washed in 3% FCS/0.1% NaN 3 /1ϫ phosphate-buffered saline [PBS; fluorescein-activated cell sorter (FACS) wash] , followed by incubation with 5 g heat-aggregated IgG to inhibit nonspecific binding. Cells were incubated for 45 min at 4°C with saturating amounts of fluorescein isothiocyanate (FITC)-conjugated monoclonal antibodies (mAb) against CD23, CD38, CD40, and CD11a (Ancell, Bayport, MN) and biotin-conjugated mAb against CD20, CD54, CD80, CD86, major histocompatibility complex (MHC) II (Ancell), or the matched isotype controls. Cells were washed in FACS wash, and biotin-conjugated samples were further incubated with 20 l (1:10 dilution) phycoerythrin-conjugated streptavidin for 30 min at 4°C. Cells were washed, fixed with 1% paraformaldehyde in 1ϫ PBS, and analyzed by FACS using an Epics Profile II flow cytometer (Coulter Electronics, Hialeah, FL) or a FACScan (Becton Dickinson, Mountain View, CA).
Protein immunoblots
Cell extracts were prepared by lysis in 50 mM Tris-HCl (pH 8)/1 mM EDTA/1% Nonidet P-40/150 mM NaCl. Equal amounts of protein were separated by electrophoresis on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred onto polyvinylidene difluoride membrane (Schleicher and Schuell, Keene, NH), and detected with antibodies against LMP1 and EBNA2 (Dako, Carpinteria, CA). Horseradish peroxidase-conjugated second-ary antibodies were used for detection by enhanced chemiluminescence (Amersham, Piscataway, NJ).
and 293/CD40L membrane isolation
Cell membranes were isolated according to previously published techniques [45] . Briefly, 293 or 293/CD40L cells were incubated in Complete medium containing 100 g/mL ␣-methyl-D-mannoside (Sigma Chemical Co., St. Louis, MO) at 37°C for 1 h. Cells were washed twice in ice-cold 1ϫ PBS containing 100 g/mL ␣-methyl-D-mannoside, resuspended at 5 ϫ 10 6 cells/mL in ice-cold homogenization buffer [100 g/mL ␣-methyl-D-mannoside, 20 mM Tris-Cl, 10 mM NaCl, 0.1 mM MgCl 2, 0.1 mM phenylmethylsulfonyl fluoride (Sigma Chemical Co.), 0.5 g/mL DNase-I (Sigma Chemical Co.)], and homogenized to detach the membranes. Cell debris was separated from the membranes over a 41% surcrose cushion by ultracentrifugation for 1 h at 9500 g. The interfacial membrane band was isolated, washed in RPMI, and pelleted by centrifugation at 35 k for 45 min. Membranes were resuspended at 3 ϫ 10 7 cell equivalents/100 l Complete medium.
Proliferation assay
Parallel cultures of LCLs were established at 5 ϫ 10 4 cells/well/100 l in flat-bottom 96-well plates with 293 or 293/CD40L membranes (at a final dilution of 1:10) for 24 h to assay cellular growth by [ 3 H]thymidine incorporation. Cells were pulsed with 0.5 Ci [
3 H]thymidine (Perkin Elmer, Boston, MA) during the last 6 h of culture before lysis by one round of freezing and thawing. Cells were harvested onto a glass fiber filtermat with a semiautomatic cell harvester (Skatron Instruments, Sterling, VA) and counted on a Beckman LS analyzer.
Statistical analysis
For comparison of two samples, a two-tailed Student's t-test was used. Significance was set at P Ͻ 0.05. Data in figures and tables are shown as mean Ϯ SD unless otherwise indicated.
RESULTS
pt1-LCLs show a partially activated phenotype with respect to a subset of cell-surface proteins
To generate standard LCLs, pt1 and control PBMCs were infected with EBV and cultured continuously for a period of 3-5 weeks prior to analysis. Determination of viral expression by Western analysis and reverse transcriptase-PCR for EBVtransforming proteins EBNA1, EBNA2, EBNA2A, EBNA3A, EBNA3C, and LMP1 revealed no difference in pt1-LCLs relative to control lines (data not shown). As noted above, a clear defect in pt1 primary B cells was their failure to express CD23 at a normal level after activation with CD40L [19] . As CD23 expression is generally highly elevated in LCLs, we sought to characterize the phenotype of pt1-LCLs relative to control LCLs, focusing on the expression of CD23 as well as other lineage-and activation-specific markers. For control lines, we chose LCLs with a range of phenotypes with respect to surface Ig expression and growth in culture (C3121, IgG ). In particular, we analyzed two different IgM ϩ lines to establish a range of marker expression in transformed B cells from control individuals. As presented in Table 1 and shown representatively in Figure 1 , the expression of CD23 [both percent-positive cells and mean fluorescent intensity (MFI)] was down-regulated markedly in the pt1 relative to control LCLs. Other surface markers such as CD11a, CD80, and MHC II, which are normally induced in response to EBV infection, fell within the normal range of control LCLs. However, the MFIs of CD54 (ICAM-1) and CD40 were reduced, and the MFI of CD86 was increased relative to controls. Also of note was that CD38, which is generally down-regulated on LCLs, was highly expressed on pt1 and C3688. A profile of reduced CD23, CD40, ICAM-1, and elevated CD38 expression is inconsistent with the phenotype of the fully activated LCL and more closely resembles the pt1 primary B cells upon CD40L stimulation (ref. [19] and data not shown). Additionally, the finding that CD80 expression is indistinguishable from control LCL levels extends our previous finding that CD40-induced CD80 expression in primary B cells is not affected by the pt1 mutation [19] .
Extended signaling through LMP1 changes the phenotypic profile of the pt1-LCLs
The fact that LMP1 constitutively signals through the CD40 pathway suggested that a subset of pt1 defective responses, which revert with sustained signaling, may also be reversed by LMP1 expression over an extended period of time. To test this possibility, pt1-LCL (CD23 lo /CD38 hi ) and control C3121-LCL (CD23 hi /CD38 lo ) populations were analyzed over a 4-week period for changes in CD23 and CD38 expression. As shown in Figure 2 (upper panels), there was a notable change in CD23 expression in percent-positive and MFI in the pt1-LCL population (from 13.8%/27 to 79.1%/68.6) and little change in the percent-positive of the control population over the period studied (98%/354.7-97.9%/143.1). Within the same time course, we also observed a decrease in the expression of CD38 in pt1-LCLs (from 94.4%/113.8 to 88%/42.3) and control LCLs (from 4.2%/22.8 to 2%/8.1; lower panels). The increase in CD23 and decrease in CD38 expression are consistent with the pt1-LCL population, acquiring a more plasmacytoid phenotype resulting from constitutive signaling through LMP1 or through the selective outgrowth of a small LMP1 ϩ /CD23 ϩ population.
Establishment of LCL tet cells
To circumvent the loss of the CD40 defect, as measured by low CD23 expression, we used an alternative EBV-based system that uses a recombinant EBV genome (p1852), which condi- were transferred from tet-containing (tet ϩ ) media and cultured in the absence of tetracycline (tet -) for 3 days before culturing the cells for an additional 4 days in tet ϩ media. Total extracts were collected from cultures at each time-point, and LMP1 expression was examined by Western blot (Fig. 3A) . The p1852 plasmid contains only the LMP1 gene under the control of the tetR-KRAB repressor. To verify that only LMP1 expression is regulated by tet, the same blot was analyzed for EBNA2 expression. In the absence of tet, LMP1 expression was dramatically decreased by Day 1 and remained low-to-absent during the time-period examined (left panels). During the same time-period, the levels of EBNA2 remained unchanged in each clone. Addition of tet led to the reinduction and sustained expression of LMP1 without affecting EBNA2 expression (right panels). We also examined other viral genes by Western or quantitative PCR and found the expression levels were not affected by the addition or removal of tetracycline (data not shown).
To confirm that a LMP1-mediated function was regulated directly by tet in the LCL tet population, cell proliferation was measured in cultures grown in the continuous presence ( ϩ tet cont, solid black line), continuous absence ( -tet cont, solid gray line), or the absence and then readdition ( -/ϩ tet, stippled line) of tet during a 6-day period (Fig. 3B) . In the ϩ tet cont cultures, there was a similar level of sustained proliferation in control LCL tet populations (middle and bottom panels) as well as in the pt1-LCL tet population (top panel). In contrast, there was an initial, gradual growth arrest, which corresponded directly to the cessation of LMP1 expression in the -/ϩ tet cultures. Upon readdition of tet at day 3, proliferation increased to the ϩ tet cont levels, paralleling the reinduction of LMP1 expression. These results indicate that the pt1-LCL tet cells are dividing in response to signals through LMP1 and that if there is an intrinsic defect in the CD40-mediated proliferation, it is not recapitulated with LMP1 signaling. 
Maintenance of defective CD23 expression in pt1-LCL tet cells
To determine the pattern of CD23 and CD38 expression, pt1-LCL tet and control LCL tet populations were surface-stained and FACS analyzed after a continuous 4-week culture in tet ϩ media followed by an additional 3-day incubation in tet ϩ or tet -media. Also, to assess the extent of CD23 and CD38 expression after stimulation with CD40L in the absence of LMP1 expression, cells incubated in tet -media for 3 days were transferred into media containing soluble CD40L for an additional day. As shown in Figure 4 , pt1-LCL tet cells grown in the presence of tet (ϩLMP1, top left panel, black line) express a lower level of CD23 on their surfaces compared with both control cell lines (middle and bottom left panels, black lines). When cells were shifted to tet -media, there was no change in the expression pattern of CD23 in pt1-LCL tet cells and only a modest decrease in CD23 expression in D11-LCL tet and C2-LCL tet cells (compare top left to middle and bottom left panels, dashed lines). Upon stimulation with CD40L in the absence of LMP1, CD23 levels increased slightly in pt1 and control C2 cells only (left panels, gray line). Together, these results reveal that the level of CD23 expression in the LCL tet lines is relatively independent of changes in LMP1 expression and that signaling through CD40 can induce a small shift in expression in the LCL tet lines. In the presence of LMP1, there was a high level of surface CD38 expression in pt-LCL tet cells. However, similar to our CD23 observation, there was no measurable change in CD38 expression in the absence of LMP1 or upon restimulation with CD40L (top right panel). In contrast, both control lines showed low CD38 expression in the presence of LMP1 and a concomitant and rapid increase in the absence of LMP1 (middle and bottom right panels). Addition of CD40L resulted in the downregulation of CD38 in the control cells, returning to levels at or below that seen with LMP1 (middle and bottom right panels, gray line). These experiments revealed that signaling through LMP1 or CD40 can down-regulate CD38 expression in the control but not the pt1-LCL tet cells. The loss of this LMP1/ CD40-mediated function suggests that an additional factor 
CD40-mediated proliferation defect in pt1-LCL tet cells
To further study the CD40 defect in pt1 B cells, we measured and compared the CD40-specific proliferation response of pt1-LCL tet cells to control LCL tet cells. Our initial work demonstrated a minimal difference in the growth of pt1-LCL tet and control LCL tet lines under different conditions of LMP1 expression (Fig. 3B) . However, results from Figure 4 suggested that low CD23 expression was not complemented in pt-LCL tet cells in the presence of LMP1 or CD40 signaling. A hallmark feature of CD40 activation is that it stimulates proliferation of non-EBV-immortalized B cells and inhibits growth of EBV-immortalized B cells by arresting cells in G 0 /G 1 [46] . Thus, these lines provide an ideal system to study the effect of CD40 activation on proliferation in the presence or absence of LMP1 signaling. LCL tet cells were cultured with tet (Fig. 5A , "LMP1 on") or without tet for 3 days (Fig. 5B , "LMP1 off") and then further cocultured for an additional 24 h with isolated membranes from 293 cells (unstimulated) or 293 cells expressing CD40L (CD40-stimulated). As shown in Figure 5A , costimulation of pt1 and control LCL tet populations with LMP1 and 293/CD40L membranes resulted in decreased proliferation compared with cells costimulated with 293 membranes alone. This suggests that negative proliferative signals transduced through CD40, in the context of sustained LMP1 signaling, are integrated normally in pt1-LCL tet cells. In contrast, when cells were cultured in tet -media for 3 days and then stimulated with CD40L-expressing membranes, a different response was observed between pt1 and control cells. Although control D11-and C2-LCL tet cells had significant increases in proliferation in response to CD40L, pt1-LCL tet cells showed no significant change under these conditions (Fig. 5B) . The limited growth response of pt1-LCL tet cells indicates that the CD40-related defect may also directly affect proliferation. This was further confirmed by assaying the proliferative response of primary pt1 B cells to CD40L and observing a distinct defect in CD40-induced cell growth (data not shown). These results provide further evidence for impaired CD40 signaling in pt1 B cells and support the hypothesis that the defect is manifested in aberrant proliferation, as well as low-to-absent CD23 expression and CSR. Also, we demonstrate that unlike CD23 expression, defective proliferation can be complemented by signals through LMP1 but not through CD40.
DISCUSSION
Identifying novel defects that involve CD40 signaling can be challenging, given that EBV, which is the primary method for immortalizing human B cells, appropriates the CD40 pathway in a ligand-independent manner (reviewed in ref. [47] ). Accordingly, constitutive LMP1-dependent signaling through the TRAF adaptor molecules may mask defective responses that are otherwise evident under regulated levels of signal. In this report, we used conventional and tet-regulated, EBV-mediated transformation to immortalize B cells from a non-X-linked HIGM patient. A comparison of phenotypic and functional characteristics of at least three different clones of pt1 and control LCL populations revealed a number of novel findings. It is important that we found that conventional LCLs lose the CD23 lo /CD38 hi phenotype observable in pt1 primary B cells and therefore have limited use with respect to studying the defect in impaired CD40 signaling. In contrast, pt1-LCL tet cells cultured in the presence or absence of LMP1 or CD40L maintain the specific CD23 lo /CD38
hi phenotype over an extended period of time. Also, we observed that signals through LMP1 and CD40 separately regulate the expression of CD38 and to a much lesser degree, CD23, in control LCL tet cells and that these signals fail to appreciably modulate the expression of CD38 or CD23 in pt1-LCL tet cells. Finally, we show that CD40-induced proliferation is also severely reduced in the pt1-LCL tet cells and that normal levels of cell cycling are achieved only by signaling through LMP1 and not CD40.
Overall, these results are consistent with the pt1 defect residing in the CD40-mediated signal-transduction pathways leading to CD23 expression and mitogenic activation. Also, our results support a model of sustained signaling through tetregulated LMP1 expression, complementing some aspects of the pt1 defect (i.e., proliferation) but not others (i.e., CD23 expression). Observed differences in the response to CD40 and/or LMP1 signals extend previous findings that these two molecules use separate as well as overlapping signaling pathways to drive B cell proliferation and differentiation (reviewed in ref. [48] ). Specifically, mice lacking CD40 and expressing a transgenic LMP1 restore many, but not all, of the CD40-specific functions [35] . Also, CD40L activation of CD40 in mouse B cells induces a subset of RNAs that are not upregulated in LMP1-activated B cells [49, 50] . These differences in responses may be explained by the fact that distinct subsets of adaptor molecules bind with different affinities to LMP1 and CD40 [51, 52] , and LMP1 produces amplified and/or sustained activation responses relative to CD40 in in vitro and in vivo experiments [53] [54] [55] . The mechanistic basis of these stronger signals is likely related to the fact that signaling through CD40, but not LMP1, results in ubiquitinand proteasome-dependent TRAF2 and TRAF3 degradation [53, 56] and that LMP1 forms a higher order complex than the trimeric signaling complex induced by CD40L-CD40 ligation [57, 58] .
Given the potency of LMP1 signals, we were surprised to find that restoration of high levels of CD23 expression was observed only in conventional LCLs and not in the LCL tet cells. One explanation for this finding may be that the expression is not being complemented by LMP1 directly, but rather, there is a distinct growth advantage in the traditional LCLs for CD23 ϩ cells. This growth advantage could be related to overlapping pathways of regulation of LMP1 and CD23, only in LCLs and not in mini-EBV-transformed LCL tet cells. For example, after EBV infection of B cells and immediate expression of EBNA2 and EBNA5, there is a distinct lag in LMP1 expression, which appears to precede or coincide with initiation of DNA synthesis [59 -63] . Accordingly, EBNA2 has been shown to be necessary for the efficient expression of LMP1 in B cells [64 -66] , and LMP1 is critical for EBV-mediated B cell proliferation and transformation [43, 67] . If a common signaling or transcription factor required for LMP1 and CD23 expression is affected in pt1B cells, then under conditions of standard EBV immortalization, there would be a strong, selective advantage for growth of LMP1 ϩ /CD23 ϩ pt1 B cells. In contrast, in the LCL tet system, LMP1 is expressed from a heterologous promoter, and therefore, the expression of CD23 and LMP1 is formally "unlinked." Thus, the small number of CD23 ϩ cells would not necessarily be at a selective growth advantage, and the population would remain predominantly CD23 -. Recent data support the premise that LMP1 mediates proliferation through the induction of c-myc and Jun/activated protein-1 family members. In particular, c-myc expression is up-regulated within 30 min of LMP1 signals [50] . Also, CD40 activation turns on many of the same genes involved in cellcycle regulation, and in LMP1-and CD40-activated B cells, induction of c-myc appears to be independent of new protein synthesis [49, 50] . In light of these findings and the fact that the pt1 defect appears to be B cell-specific, we would hypothesize that c-myc is induced by LMP1 but not by CD40 signals. The fact that we see complementation of the proliferation defect only with LMP1 reinforces the idea that a higher threshold of signal is required to overcome the downstream defect. It is interesting that we see a decrease in proliferation in control and pt1-LCL tet cells when they receive signals through LMP1 and CD40 compared with LMP1 alone. This suggests that when pt1-LCL tet cells are being induced to proliferate through LMP1, they are able to respond to CD40 signaling, further supporting the idea that the signal provided by LMP1 is overcoming the proliferation defect. Dissection of the LMP1 and CD40 signaling pathways leading to c-myc expression in control LCL tet and pt-LCL tet lines is currently ongoing. In summary, our findings support the use of the mini-EBV system as a viable means to maintain the pt1 primary B cell phenotype in long-term culture. Defects in CD23 expression and CD40-mediated cell proliferation demonstrate impaired CD40 activation and signaling in the pt1 B cells. Thus, the LCL tet cells provide a functional model system to further localize the defect in pt1 B cells and study the independent effects of LMP1-and CD40-mediated signals on downstream responses in normal and immunodeficient B cells.
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